Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

THERANEXUS : and BBDF obtain European "orphan medicinal product" designation for BBDF-101 in Batten disease

10/21/2020 | 12:20pm EST

THERANEXUS AND BBDF OBTAIN EUROPEAN "ORPHAN MEDICINAL PRODUCT" DESIGNATION

FOR BBDF-101 IN BATTEN DISEASE

Lyon, 21 October 2020 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF) today announced the European Commission's decision to award "orphan medicinal product" designation to the two active ingredients, trehalose and miglustat, used in the drug candidate BBDF-101 for Batten disease, a rare, fatal genetic disorder affecting the metabolism of the central nervous system for which there is currently no treatment.

Under the agreement between Theranexus and BBDF, Theranexus has an exclusive, global license for the development and commercial use of its drug candidate BBDF-101 for juvenile Batten disease. BBDF-101 is a proprietary combination of trehalose and miglustat, two active ingredients which each have a specific role and work in synergy to restore normal metabolic activity in brain cells.

"After obtaining Orphan Drug Designation from the FDA in August, we are delighted to have secured the same status for Europe. During the summer we launched preclinical studies to confirm the safety of BBDF-101 over a long exposure time, with the aim of launching the clinical program in 2021," explains Franck Mouthon, Chairman and CEO of Theranexus.

"Orphan" drugs are aimed at diagnosing, preventing or treating very serious or life-threatening rare diseases that affect no more than 5 in 10,000 people in the European Union. This status gives Theranexus ten years of market exclusivity in the European Union once the drug has been granted marketing authorization. The Company will also receive scientific advice from the European Medicines Agency (EMA) to ensure that it complies with European regulatory requirements and will have direct access to the centralized marketing authorization procedure. Orphan designation also exempts the Company from paying the fees associated with the submission of the marketing authorization application.

ABOUT THERANEXUS

Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as "glial cells") in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.

The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX). More information at: www.theranexus.com

Plus d'informations sur

http://www.theranexus.com

Cliquez et suivez-nous sur Twitter et Linkedln

Contacts

THERANEXUS

Thierry LAMBERT

Directeur Administratif et Financier investisseurs@theranexus.fr

FP2COM

Florence PORTEJOIE

Relations Médias

  • 33 (0)6 07 76 82 83 fportejoie@fp2com.fr

ACTUS finance & communication

Guillaume LE FLOCH Relations Investisseurs +33 (0)1 53 67 36 70 theranexus@actus.fr

Disclaimer

Theranexus SA published this content on 21 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 October 2020 16:19:03 UTC


© Publicnow 2020
All news about THERANEXUS
11/20THERANEXUS : - The Food And Drug Administration issues a favorable opinion on th..
AQ
11/20THERANEXUS : The Food And Drug Administration (FDA) issues a favorable opinion o..
PU
11/19THERANEXUS : The food and drug administration (fda) issues a favorable opinion o..
AN
11/05THERANEXUS : - Presentation of the results of the phase 1b clinical study with T..
AQ
11/04THERANEXUS : Presentation of the results of the phase 1b clinical study of THN20..
PU
11/04THERANEXUS : Presentation of the results of the phase ib clinical study of thn20..
AN
10/22THERANEXUS : TTHERANEXUS and the BBDF Foundation Obtain Orphan Drug Status in Eu..
AQ
10/21THERANEXUS : and BBDF obtain European "orphan medicinal product" designation for..
PU
10/16THERANEXUS : publishes its cash position as of September 30, 2020
AQ
10/15THERANEXUS : 3rd quarter earnings
CO
More news
Financials
Sales 2020 25,4 M 30,2 M 30,2 M
Net income 2020 20,1 M 23,9 M 23,9 M
Net cash 2020 58,0 M 69,0 M 69,0 M
P/E ratio 2020 2,71x
Yield 2020 -
Capitalization 55,5 M 66,1 M 66,1 M
EV / Sales 2020 -0,10x
EV / Sales 2021 0,77x
Nbr of Employees 17
Free-Float 57,4%
Chart THERANEXUS
Duration : Period :
Theranexus Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERANEXUS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 23,15 €
Last Close Price 15,00 €
Spread / Highest target 75,3%
Spread / Average Target 54,3%
Spread / Lowest Target 33,3%
EPS Revisions
Managers
NameTitle
Franck Joseph Louis Mouthon Chairman & Chief Executive Officer
Thierry Bertrand Lambert Chief Financial & Administrative Officer
Mathieu Bernard Mari Charveriat Director, Chief Scientific Officer & Deputy CEO
Werner Rein Chief Medical Officer
Dominique Costantini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERANEXUS393.42%66
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.56.53%37 691
BIONTECH SE209.80%25 273